Overview and Scope
Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its own tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. It is the most common type of lupus and cannot be cured, but medical interventions and lifestyle changes can help control it. Treatment for systemic lupus erythematosus consists mostly of immunosuppressive drugs that inhibit the immune system’s activity.
Sizing and Forecast
The systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to advancements in biologics and targeted therapies, increased understanding of disease mechanisms, clinical trials and research initiatives, government initiatives for rare disease treatment, increased awareness and diagnosis of lupus..
The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to emergence of biosimilars for lupus treatmen, integration of digital health solutions, focus on complementary and alternative medicine, innovations in immunomodulatory therapies, patient advocacy and support organizations.. Major trends in the forecast period include combinatorial therapies, personalized medicine approaches, biosimilars in sle treatment, telemedicine in sle management, educational initiatives for patients, global collaborations for lupus research..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/systemic-lupus-erythematosus-treatment-global-market-report
Segmentation & Regional Insights
The systemic lupus erythematosus treatment market covered in this report is segmented –
1) By Drug: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Immunosuppressive Drugs
2) By Route Of Administration: Sub-Cutaneous, Oral, Intravenous
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Sales
North America was the largest region in the systemic lupus erythematosus treatment market in 2023. The regions covered in the systemic lupus erythematosus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9163&type=smp
Major Driver Impacting Market Growth
The rising number of autoimmune disorders is expected to propel the growth of the systemic lupus erythematosus treatment market going forward. An autoimmune disease refers to a condition in which a patient’s immune system attacks his or her body. An autoimmune disease occurs when the immune system mistakes parts of the body as foreign. The body releases proteins called autoantibodies that attack healthy cells. Systemic lupus erythematosus refers to an autoimmune disease that causes the immune system to attack its tissues, causing widespread inflammation and tissue damage in the affected organs. It affects the joints, skin, brain, lungs, kidneys, and blood vessels. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world’s population, with 13% of women and 7% of males affected. Furthermore, in October 2021, according to an article shared by the City, University of London, a UK-based public research university, 4 million people in the UK, or 7% of the population, are estimated to have at least one autoimmune disease. Over 80 autoimmune disorders have been found, and their prevalence is increasing annually by 3–9%. Thus, the rising number of autoimmune disorders is driving the growth of the systemic lupus erythematosus treatment market.
Key Industry Players
Major companies operating in the systemic lupus erythematosus treatment market are focusing on product approvals such as zynrelef (HTX-011) to drive revenues in their market. Zynreleftm (HTX-011) is a dual-acting, extended-release local anesthetic that contains bupivacaine and meloxicam which is intended to control postoperative pain for a maximum of 72 hours. For instance, in May 2021, Heron Therapeutics, Inc. a US-based biotechnology company received FDA approval for zynrelef (HTX-011). It is intended to address the issues of pain and inflammation at the surgical site. For soft tissue or periarticular instillation, zynrelef is recommended in adults to provide postoperative analgesia up to 72 hours following foot and ankle, small-to-medium open abdomen, and lower extremity total joint arthroplasty surgical procedures. The medication is intended to deal with the problems of pain and inflammation at the surgical site. It has been clinically shown to considerably lower opioid usage after surgery and to effectively control pain over a 72-hour period, outperforming standard of care bupivacaine HCl solution.
The systemic lupus erythematosus treatment market report table of contents includes:
1. Executive Summary
2. Systemic Lupus Erythematosus Treatment Market Characteristics
3. Systemic Lupus Erythematosus Treatment Market Trends And Strategies
4. Systemic Lupus Erythematosus Treatment Market – Macro Economic Scenario
5. Global Systemic Lupus Erythematosus Treatment Market Size and Growth
.
.
.
31. Global Systemic Lupus Erythematosus Treatment Market Competitive Benchmarking
32. Global Systemic Lupus Erythematosus Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Systemic Lupus Erythematosus Treatment Market
34. Systemic Lupus Erythematosus Treatment Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
https://www.thebusinessresearchcompany.com/report/ent-devices-global-market-report
https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
